Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Temasek plans to expand investments in Indian family‑run businesses, following its $1 billion stake in Haldiram’s as it ...

Palantir Technologies Inc. (NASDAQ:PLTR) ranks among the 20 best fast growth stocks to invest in. On June 30, Palantir ...

Our platform enables insulin logs to be viewed alongside blood glucose, meals, and physical activity, offering a full circle ...

Analyst initiates coverage of WeightWatchers with a buy rating after bankruptcy reemergence. IPO hot streak continues.

Danish investor Novo Holdings, the controlling shareholder of drugmaker Novo Nordisk, is evaluating buying a stake in ...

I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and world-changing—that breakthrough would be ...

Novo Nordisk's GLP-1 Market Growth (Novo Nordisk's Q1-2025 Investor Presentation) The next risk is drug pricing reform in the US, as it could pressure margins.

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss drug.